• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » pSivida-Alimera eye treatment still a no-go for the FDA

pSivida-Alimera eye treatment still a no-go for the FDA

November 11, 2011 By MassDevice staff

The FDA rejected pSivida Corp.’s (NSDQ:PSDV) and Alimera Sciences Inc.’s (NSDQ:ALIM)  resubmitted new drug application for the Iluvien eye treatment, citing a lack of safety and efficacy data.

Iluvien is designed to deliver sustained, low doses of flucocinolone acetonide to the retina at the rear of the eyeball in patients with diabetic macular edema.

The federal watchdog agency said the risk of reaction shown in the companies’ clinical study were significant and that the NDA did not provide sufficient data to prove that the drug’s benefits outweighed its risks.

Sign up to get our free newsletters delivered straight to your inbox

The FDA called for two additional clinical trials to demonstrate Iluvien’s safety and efficacy in treating diabetic macular edema.

"We are obviously surprised and disappointed with the FDA’s decision," Paul Ashton, president & CEO of pSivida said in prepared remarks.

Watertown, Mass.-based pSivida’s partner Alimera resubmitted a new drug application to the federal watchdog agency in May, 11 months after the companies’ first NDA.

The companies received a rejection letter from the FDA for the drug-device combination last December.

The FDA requested additional analysis of safety and efficacy data from the companies’ FAME study along with additional information on specifications on the manufacturing, packaging and sterilization of the drug by third-party manufacturers, according to the companies.

"We believe the additional data we recently released will help the FDA further evaluate the safety and efficacy of Iluvien," said Alimera CEO Dan Myers when the NDA was resubmitted." In addition, the third-party manufacturing deficiencies identified in the CRL have been resolved."

Upon approval of Iluvien, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits of the drug, the company said.

pSivida will hold a press conference to discuss the FDA’s decision on Monday, Nov. 14 at 9:00am.

Filed Under: Food & Drug Administration (FDA), News Well, Optical/Ophthalmic, Pharmaceutical Tagged With: Alimera Sciences, pSivida Corp.

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy